Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs FuturHealth

CoreAge Rx
Graded #1

Higher grade

vs+26.200000000000003
FuturHealth
Graded #215

Lower grade

The verdict

CoreAge Rx takes it — 91.8/100 to 65.6/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoreAge Rx +32
92
60
Dose & formulationCoreAge Rx +7
88
81
Clinical oversightCoreAge Rx +26
93
67
Labs & monitoringCoreAge Rx +29
90
61
FulfillmentCoreAge Rx +33
95
62
Contract termsCoreAge Rx +41
96
55
CoreAge Rx · left barFuturHealth · right bar

The numbers

MetricCoreAge RxFuturHealth
WeighScore91.8/10065.6/100
GradeA−C
Scorecard rank#1#215
Semaglutide$149/mo$199/mo (compounded)
Tirzepatide$349/moNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
CoreAge Rx

Graded #1 · A−

Strengths

  • Flat all-in price with no month-two step-up
  • Semaglutide and tirzepatide on one account
  • All 50 states, LegitScript-verified

Where it loses points

  • Not the cheapest sticker price
  • Compounded only
  • Pharmacy partner not yet publicly named
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard